Slide 1: Third Quarter 2018 Financial Results & Update
Third Quarter 2018 Financial Results & Update October 23, 2018 Exhibit 99.2
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the fu
Slide 3: Third Quarter Earnings Call Agenda
Third Quarter Earnings Call Agenda Q3 Financial Results & 2018 Guidance Jim Frates Chief Financial Officer Commercial Update Jim Robinson President & Chief Operating Officer Business Update Richard Pops Chief Executive Officer
Slide 4: Third Quarter 2018 Revenue Summary
Third Quarter 2018 Revenue Summary In millions, except % Q3’18 Q3’17 ∆ Q3’18 VS. Q3’17 VIVITROL® $79.9 $69.2 15% ARISTADA® $36.1 $24.5 48% Manufacturing & Royalty Revenues $116.4 $122.7 -5% R&D Revenues $16.3 $1.0 Total Revenues $248.7 $217.4 14% Total Revenues ($M)
Slide 5: Revenues From Proprietary Commercial Medicines
Revenues From Proprietary Commercial Medicines Proprietary Commercial Product Revenues ($M)
Slide 6: VIVITROL Performance
VIVITROL® Performance Q3 year-over-year net sales growth of 15%, driven by underlying unit growth of 18% Q3’18 results reflect estimated 48% Medicaid units Net sales increased 5% sequentially, driven by favorable gross-to-net variability Gross-to-net deductions of 47% in Q3’18, compared to 49% in Q2
Slide 7: ARISTADA Performance
Q3 year-over-year net sales growth of 48% Sequential growth of 8% compared to Q2’18 Approximately 47% gross-to-net deductions, compared to 43% in Q2’18 and 41% in Q3’17 2018 net sales expectations of $140M - $160M ARISTADA® Performance ARISTADA Quarterly Net Sales ($M)
Slide 8: Alkermes: Updated 2018 Financial Expectations
(in millions, except per share amounts) Financial Expectations for Year Ending Dec. 31, 2018† Revenues $1,015 – 1,045 COGS $180 – 190 R&D Expense $415 – 445 SG&A Expense $515 – 545 Amortization of Intangible Assets ~$65 Net Interest Expense ~$10 Income Tax Expense $0 – 10 GAAP Net Loss $(180) – (210
Slide 9: State and federal dollars are being allocated; funding slowly flowing into fragmented treatment system
State and federal dollars are being allocated; Funding slowly flowing into fragmented treatment system ~$2B of federal funding has been distributed to states via block grants Small percentage has flowed from the states into changing the treatment system New opioid legislation, SUPPORT for Patients a
Slide 10: ARISTADA: Gaining Traction With Launch of ARISTADA INITIO
ARISTADA INITIO now available ARISTADA INITIO regimen* provides an opportunity to initiate patients onto any dose of ARISTADA on day 1 ARISTADA INITIO in conjunction with two-month ARISTADA resonating with treatment providers and patients Early coverage additions to key hospital and Medicare Part D
Slide 11: ALKS 5461
Investigational product for adjunctive treatment of major depressive disorder (MDD) Opioid system modulator represents a new mechanism of action for the treatment of MDD Program Status Regulatory review underway, PDUFA target action date Jan. 31, 2019 FDA Advisory Committee meeting scheduled for Nov
Slide 12: ALKS 3831
ALKS 3831 Investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia Designed to provide antipsychotic efficacy of olanzapine and a differentiated safety profile with favorable weight and metabolic properties Positive results from ENLIGHTEN-1 pi
Slide 13: BIIB098 (Diroximel Fumarate)
BIIB098 (Diroximel Fumarate) Investigational product for the treatment of relapsing forms of multiple sclerosis (MS) License and collaboration agreement with Biogen announced in Q4’17 Received $50M payment from Biogen following its preliminary review of GI tolerability data from ongoing clinical pro
Slide 14: ALKS 4230
ALKS 4230 Novel immuno-oncology candidate Designed to selectively activate intermediate-affinity IL-2 receptors to enhance tumor-killing immune cells Monotherapy dose-escalation stage of phase 1 study ongoing Initiated evaluation of safety and anti-tumor activity of ALKS 4230 in combination with pem
Slide 15: Significant News Flow Expected in 2018
ARISTADA®: New initiation product approved ARISTADA INITIO® approved June 29 ALKS 5461: Regulatory review underway NDA accepted for filing Advisory Committee meeting scheduled for Nov. 1 ALKS 3831: Data from second pivotal study ENLIGHTEN-2 weight study enrollment completion Metabolic study data pre
Slide 16: www.alkermes.com
” www.alkermes.com